
Filter News
Area of Research
- Biological Systems (1)
- Biology and Environment (16)
- Computational Biology (2)
- Computational Engineering (1)
- Energy Science (7)
- Fusion and Fission (1)
- Isotopes (6)
- Materials (7)
- Materials for Computing (2)
- National Security (2)
- Neutron Science (14)
- Nuclear Science and Technology (2)
- Supercomputing (17)
News Topics
- (-) Biomedical (72)
- (-) Statistics (4)
- 3-D Printing/Advanced Manufacturing (141)
- Advanced Reactors (40)
- Artificial Intelligence (123)
- Big Data (77)
- Bioenergy (105)
- Biology (121)
- Biotechnology (33)
- Buildings (73)
- Chemical Sciences (84)
- Clean Water (32)
- Composites (33)
- Computer Science (222)
- Coronavirus (48)
- Critical Materials (29)
- Cybersecurity (35)
- Education (5)
- Element Discovery (1)
- Emergency (4)
- Energy Storage (114)
- Environment (217)
- Exascale Computing (64)
- Fossil Energy (8)
- Frontier (62)
- Fusion (65)
- Grid (73)
- High-Performance Computing (128)
- Hydropower (12)
- Irradiation (3)
- Isotopes (62)
- ITER (9)
- Machine Learning (66)
- Materials (156)
- Materials Science (155)
- Mathematics (12)
- Mercury (12)
- Microelectronics (4)
- Microscopy (55)
- Molten Salt (10)
- Nanotechnology (62)
- National Security (85)
- Neutron Science (169)
- Nuclear Energy (121)
- Partnerships (65)
- Physics (68)
- Polymers (34)
- Quantum Computing (50)
- Quantum Science (86)
- Security (30)
- Simulation (64)
- Software (1)
- Space Exploration (26)
- Summit (70)
- Transportation (102)
Media Contacts
Connect with ORNL
Get ORNL News

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.

Thirty-two 91°µÍø employees were named among teams recognized by former DOE Secretary Dan Brouillette with Secretary’s Honor Awards as he completed his term. Four teams received new awards that reflect DOE responses to the coronavirus pandemic.
91°µÍø and collaborators have discovered that signaling molecules known to trigger symbiosis between plants and soil bacteria are also used by almost all fungi as chemical signals to communicate with each other.

A multi-institutional team, led by a group of investigators at 91°µÍø, has been studying various SARS-CoV-2 protein targets, including the virus’s main protease. The feat has earned the team a finalist nomination for the Association of Computing Machinery, or ACM, Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.

NellOne Therapeutics has licensed a drug delivery system from the Department of Energy’s 91°µÍø that is designed to transport therapeutics directly to cells infected by SARS-CoV-2, the virus causing COVID-19.

Scientists from 91°µÍø used high-performance computing to create protein models that helped reveal how the outer membrane is tethered to the cell membrane in certain bacteria.

When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.

To better understand how the novel coronavirus behaves and how it can be stopped, scientists have completed a three-dimensional map that reveals the location of every atom in an enzyme molecule critical to SARS-CoV-2 reproduction.